Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
出版年份 2021 全文链接
标题
Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 1, Pages 369
出版商
MDPI AG
发表日期
2021-12-30
DOI
10.3390/ijms23010369
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes
- (2020) Nicole Kiweler et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Identifying drug targets in tissues and whole blood with thermal-shift profiling
- (2020) Jessica Perrin et al. NATURE BIOTECHNOLOGY
- Role of Histone Deacetylases in Carcinogenesis: Potential Role in Cholangiocarcinoma
- (2020) Kishor Pant et al. Cells
- Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials
- (2020) Leslie Padrnos et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Givinostat: an emerging treatment for polycythemia vera
- (2020) Helen T. Chifotides et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group
- (2020) Jian Liu et al. ACS Medicinal Chemistry Letters
- A Class I Histone Deacetylase Inhibitor Attenuates Insulin Resistance and Inflammation in Palmitate-Treated C2C12 Myotubes and Muscle of HF/HFr Diet Mice
- (2020) Soo Jin Lee et al. Frontiers in Pharmacology
- Sirtuin-1 in immunotherapy: A Janus-headed target
- (2019) Sakshum Chadha et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases
- (2019) Joseph Cioccio et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Chemical genomics reveals histone deacetylases are required for core regulatory transcription
- (2019) Berkley E. Gryder et al. Nature Communications
- HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1
- (2019) Mandy Beyer et al. Cancers
- One-Atom Substitution Enables Direct and Continuous Monitoring of Histone Deacylase Activity
- (2019) Matthes Zessin et al. BIOCHEMISTRY
- Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
- (2019) Zsófia Kutil et al. ACS Omega
- Histone Deacetylase 11 Is a Fatty-Acid Deacylase
- (2018) Zsofia Kutil et al. ACS Chemical Biology
- Zinc binding groups for histone deacetylase inhibitors
- (2018) Lei Zhang et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
- (2018) et al. MOLECULES
- Metformin facilitates BG45‑induced apoptosis via an anti‑Warburg effect in cholangiocarcinoma cells
- (2018) Dehua Tang et al. ONCOLOGY REPORTS
- Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
- (2018) Loredana Cappellacci et al. CURRENT MEDICINAL CHEMISTRY
- Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
- (2018) Johanna Ungerstedt INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants
- (2018) Martin Marek et al. JOURNAL OF MEDICINAL CHEMISTRY
- Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia
- (2018) Bowen Yan et al. LEUKEMIA
- Panobinostat for the management of multiple myeloma
- (2017) Dharshan Sivaraj et al. Future Oncology
- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
- (2017) Masamichi Mori et al. INVESTIGATIONAL NEW DRUGS
- Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity
- (2017) Tino Heimburg et al. JOURNAL OF MEDICINAL CHEMISTRY
- The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy
- (2017) Lin-Lin Cao et al. Oncotarget
- Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study
- (2017) Nilofer S. Azad et al. Oncotarget
- Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors
- (2016) Florence F. Wagner et al. BIOORGANIC & MEDICINAL CHEMISTRY
- ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
- (2016) C. L. Batlevi et al. HAEMATOLOGICA
- Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat
- (2016) Isabelle Becher et al. Nature Chemical Biology
- HDACs and HDAC Inhibitors in Cancer Development and Therapy
- (2016) Yixuan Li et al. Cold Spring Harbor Perspectives in Medicine
- ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
- (2016) C. L. Batlevi et al. HAEMATOLOGICA
- An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection
- (2015) Florence F. Wagner et al. ACS Chemical Biology
- Metabolic Regulation of Histone Post-Translational Modifications
- (2015) Jing Fan et al. ACS Chemical Biology
- Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors-What Some May Have Forgotten or Would Rather Forget?
- (2015) Sida Shen et al. ChemMedChem
- Histone deacetylases: structural determinants of inhibitor selectivity
- (2015) Carmina Micelli et al. DRUG DISCOVERY TODAY
- Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors
- (2015) Jin Cai et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins
- (2015) Edward Harder et al. Journal of Chemical Theory and Computation
- Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators
- (2015) Peng Zhan et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Comprehensive View of the Epigenetic Landscape. Part II: Histone Post-translational Modification, Nucleosome Level, and Chromatin Regulation by ncRNAs
- (2014) Anna Sadakierska-Chudy et al. NEUROTOXICITY RESEARCH
- ProTox: a web server for the in silico prediction of rodent oral toxicity
- (2014) Malgorzata N. Drwal et al. NUCLEIC ACIDS RESEARCH
- Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment
- (2014) De-Si Pan et al. MedChemComm
- Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia
- (2013) Michel Weïwer et al. Future Medicinal Chemistry
- Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability
- (2013) Benjamin E. L. Lauffer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data
- (2013) Daniel R. Roe et al. Journal of Chemical Theory and Computation
- Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
- (2013) J Minami et al. LEUKEMIA
- Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo
- (2013) Wenwen Chien et al. MOLECULAR CARCINOGENESIS
- Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases
- (2013) Florence F. Wagner et al. Neurotherapeutics
- HDAC Up-Regulation in Early Colon Field Carcinogenesis Is Involved in Cell Tumorigenicity through Regulation of Chromatin Structure
- (2013) Yolanda Stypula-Cyrus et al. PLoS One
- Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
- (2012) Berkley E Gryder et al. Future Medicinal Chemistry
- Epigenetic protein families: a new frontier for drug discovery
- (2012) Cheryl H. Arrowsmith et al. NATURE REVIEWS DRUG DISCOVERY
- Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
- (2011) Zhi-Qiang Ning et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inhibitors of HDACs - Effective Drugs Against Cancer?
- (2010) S. Muller et al. CURRENT CANCER DRUG TARGETS
- New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
- (2010) Jonathan B. Baell et al. JOURNAL OF MEDICINAL CHEMISTRY
- JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
- (2009) J. Arts et al. CLINICAL CANCER RESEARCH
- Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
- (2008) Florian R Fritzsche et al. BMC CANCER
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
- (2008) W Weichert et al. BRITISH JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More